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Summary Soluble and nuclear oestrogen receptor status was determined in both the central and peripheral
portions.of tumour for 37 cases of adenocarcinoma of the endometrium. Of these, 29 had functional receptor
in the peripheral biopsy, but only 19 retained functional receptor in the centre. Six of the 10 patients whose
tumours showed this difference came from the group of 12 patients who were immediately post-menopausal
(4.50+ 1.45 y post-menopausal age). Receptor status was not related to tumour classification into histological
grades I and II. However, receptor-negative central biopsies were significantly more likely (P<0.05) to be
Grade III. Early relapse was also related to a receptor-negative central biopsy.
Several studies have approached the problem of
intra-tumoural variation in oestrogen receptor
status in breast cancer (Tilley et al., 1978;
Silversward et al., 1980). Others have demonstrated
the advantages of measuring receptor in both
soluble and pellet fractions of each biopsy (Laing et
al., 1977; Barnes et al., 1979; Thorsen, 1979). With
the increased use of receptor status, both as an
index of prognosis (Bishop et al., 1979; Hawkins et
al., 1980; Leake et al., 1981b), and in selection of
therapy (Edwards et al., 1979; Hawkins et al., 1979;
Leake et al., 1981a), the optimum choice of tumour
section for receptor assay has become very
important in breast cancer management. Since it
has been proposed that steroid receptor status has
similar potential in the management of endometrial
cancer (Pollow et al., 1975; Bayard et al., 1978; Feil
et al., 1978; Prodi et al., 1979), a close study of
tumour sampling problems is indicated. We present
an analysis of the intra-tumoural variation of both
soluble and nuclear oestrogen receptor status in
adenocarcinoma of the endometrium.
We report that comparison of the intra- and
inter-tumour soluble and nuclear oestrogen receptor
status is best made when expressed per unit DNA.
Our results indicate that the concentration of
receptor in each fraction of receptor-positive
tumour is similar to that in normal endometrium.
We report that tumours of histological grade III,
more frequent in Sicily than elsewhere, are
significantly more likely to be receptor-negative
although receptor status does not distinguish
Grades I and II. A significant proportion of
tumours with receptor-positive peripheral biopsies
have receptor-negative central biopsies, particularly
in a group of patients who are immediately post-
menopausal.
Materials and methods
All patients attended the Obstetric and
Gynaecologic Clinic of the Policlinico or the Cancer
Hospital Centre, Palermo. All tissue was obtained
after hysterectomy. Obviously nectrotic tissue was
discarded and then parallel sections removed for
pathological examination and receptor assay. The
latter were stored in 0.25M Sucrose, 1.5mM
MgCl2, 10mM HEPES, pH 7.4, 50% Glycerol
(v/v) at -20°C until use. This storage procedure
has been found to maintain both concentration
(Leake et al., 1979; Leake, 1980) and molecular
form (Hyder & Leake, in press) of oestrogen
receptor for up to 60 days.
Where possible (37 cases out of 47) tumour tissue
was sub-divided according to its location in situ.
Sub-sections were identified as (1) peripheral (p)-
that taken from the so-called "growing" edge of the
tumour (care was taken to avoid sections from
areas of myometrial infiltration); and (2) central
(c)-that taken from non-peripheral and,
supposedly, older parts of the tumour. The term
"central" is used for convenience only, since a
physical centre for endometrial cancer is often
difficult to define. Occasional intermediate pieces (i)
were also retained from larger tumours in which
the central part could be legitimately identified.
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Oestrogen receptor assays were carried out on both
the soluble and pellet fractions of each section of
tissue. The assay (incorporating a 7-point Scatchard
plot) measured specific, high affinity binding sites
only and has been described in detail (Leake, 1980;
Leake et al., 1981a). Briefly, [3H]-oestradiol was
used as radioligand and specific binding was
suppressed in parallel incubations using 100-fold
excess of diethylstilboestrol. Unbound steroid was
removed with dextran-coated charcoal (soluble
fraction) or by extensive washing on Whatman
GF/C discs (pellet fraction). Protein content was
determined by the method of Lowry et al. (1951)
and DNA by a modification of the method of
Burton (Katzenellenbogen & Leake, 1974). For a
biopsy to be classified as positive, receptor content
had to exceed 0.2fmol,ug- 1 DNA.
Tumour tissue, confirmed pathologically as
adenocarcinoma of the endometrium, was taken
from 47 patients of whom 42 were post-
menopausal. The post-menopausal group was sub-
divided into (1) those greater than and (2) those
less than 6 y of post-menopausal age. Where
possible, sections of pathologically "normal"
endometrium was also dissected out. All other
procedures were carried out as previously described
(Leake et al., 1981a). Where appropriate, data are
quoted as mean + s.e. (no. of samples).
Results
The concentration of specific oestrogen receptor, as
calculated by Scatchard analysis, in the soluble
fraction is normally expressed per unit cytosol
protein (Bayard et al., 1978; Soutter et al., 1979;
Hawkins et al., 1980). However, all results were
also calculated relative to the DNA content of the
original homogenate. In anticipation of subsequent
statistical analysis, the "goodness of fit" to a
normal distribution curve was calculated for
receptor data relative to both protein and DNA.
For soluble receptor (ER), distribution was
abnormal when the data were expressed per unit
protein (P<0.001) whereas expressed per unit
DNA the fit was much better (0.5<P<0.75). For
nuclear receptor (ER.) and for total receptor
(ERC +ER) expressed per unit DNA a good fit was
observed (P=0.75 and 0.90, respectively). For this
reason, receptor concentrations for both soluble
and nuclear fraction is reported per unit DNA.
Oestrogen receptor status of the 37 cases of
endometrial cancer for which it was possible to
obtain separate central and peripheral portions is
presented in Table I. Table I also shows the
receptor status of the samples of pathologically
"normal" tissue. ERc was found in 51% (19/37) of
Table I Soluble and nuclear oestrogen receptor status of
central and peripheral portions of endometrial carcinoma
and of normal endometrium
Receptor status ERC/ERn
Tissue
type +/+ +/0 0/+ 0/0
central(c)
(n=37) 19 2 4 12
peripheral (p)
(n=37) 29 1 3 4
normal
(n= 18) 15 0 1 2
Oestrogen receptor status is reported as positive if the
Scatchard plot satisfied the usual criteria (Leake et al.,
198la) and receptor concentration exceeded
0.2fMpg-' DNA.
the central biopsies and 78% (29/37) of the
peripheral samples. Figures reported by others (70-
80% soluble receptor-positive, see Janne et al.,
.1979; Hunter et al., 1980) suggest that they are only
sampling peripheral regions or, probably, small
tumours. Functional oestrogen receptor, for the
purposes of discussion, has been defined as the
presence of measurable receptor in both the soluble
and nuclear fractions of a biopsy (Leake, 1980;
Leake et al., 1981a). It has been demonstrated in
breast cancer that the response rate to endocrine
therapy is elevated to -70% by the inclusion of
the ERn assay (Leake et al., 1981a) and that
occurrence of both ERC and ERn usually coincides
with that of progesterone receptor (Barnes et al.,
1979). Loss of functional oestrogen receptor is seen
to be common in the centre of large endometrial
tumours (18/37) but is much less common in the
peripheral regions (8/37). This difference is
significant (P<0.02). It is unlikely that this
observation could be explained in terms of necrosis
at the centre of the tumour since obviously necrotic
tissue was excluded during initial sampling and
subsequent histological examination of the parallel
sections never indicated extensive necrosis in the
sections retained. Perhaps, the most likely
explanation for the initial loss of detectable
receptor from the older parts of the tumour is the
cut-back in synthesis of "luxury" proteins in
response to the fall in blood supply. If the blood
supply is not restored then the cells may become
permanently autonomous. The number of patients
(437 for central biopsies) having receptor only in
the nucleus is high compared to the equivalent data
for breast cancer (6%) (Leake et al., 1981a) but this
represents only a small number of patients. The
supposedly normal tissue shows some abnormalities
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menopausal women (Pollow et al., 1977; Bayard et
al., 1978; Soutter et al., 1979; Levy et al., 1980)
suggesting that any endometrium from a uterus
bearing a large tumour should be regarded as
potentially abnormal.
The trend towards normality at the periphery of
the tumour is confirmed by the analysis of
intermediate sections from very large tumours.
From the data in Table II, large tumours are very
likely to yield a receptor-negative central biopsy.
The intermediate sections are less likely to be
receptor-negative and peripheral sections have a
very high chance of containing functional receptor.
Where multiple biopsies of central or peripheral
sites were possible, changes in receptor
concentration (up to 3-fold) were found but an area
classified as receptor-positive never yielded a
receptor-negative biopsy and vice versa.
Table II Receptor status of central, intermediate and
peripheral biopsies of large endometrial cancers
Receptor
status
Zone +/+ +/0 0/+ 0/0
central (c) 4 0 0 5
intermediate (i) 5 1 1 2
peripheral (p) 7 0 2 0
Receptor status indicates presence or absence of
measurable receptor in both soluble and nuclear fractions
(e.g. 0/ + indicates detectable receptor in the nuclear
fraction only).
Although receptor-negative biopsies were much
more common in the central portion of endometrial
cancer, when the mean concentration of receptor
per unit DNA (in receptor-positive samples only) is
calculated (Table III), there is no significant
difference between the central and peripheral values
for either soluble or nuclear fractions. When the
data in Table III are re-analysed according to post-
menopausal age then total receptor concentration
(ERC +ER) is significantly higher (P<0.01) in the
central portion of samples from older women
((5.11 +3.57) (28 patients) fmol.pg-' DNA) than
those in the 0-6 y post-menopausal group
(2.69+0.76 (13)). No significant difference was
found between the two post-menopausal groups for
the peripheral samples.
The distribution of patients by menopausal age
(Figure 1) confirms only a small incidence of
endometrial cancer in pre-menopausal women, a
large incidence around menopause (post-
menopausal age 0-6y, mean age 4.50+1.45 (12))
and then, perhaps, a second wave of high
incidence in the later years after menopause (post-
menopausal age >6 y, mean age 16.05 +6.67 (20)).
Table III Concentration of oestrogen receptor in the
soluble and nuclear fractions of endometrical cancer
biopsies and of normal endometrium
Receptor concentration
fmolpg 1 DNA
Tissue ERC ERn ERc+ERn
central (c)
(n= 19) 2.36+2.31
2.02+1.20
4.12±2.41
peripheral (p)
(n=29) 1.86+3.04
2.13+ 1.83
3.99+3.54
normal
(n= 14) 4.24+3.04
2.80+ 1.98
7.04+ 3.68
Values represent mean+s.e.
n=no. samples.
When the tumours were classified according to
histological grading (Table IV), it became apparent
that the disease has frequently progressed
considerably further at the time of hysterectomy
than is true in other parts of Europe or the United
States. In this study 28% of the patients had
tumours which were relatively undifferentiated
(histological grade III) whereas other recent studies
(Feil et al., 1978; Prodi et al., 1979; Hunter et al.,
1980) found only 10%, 4%, and 16% respectively
to have Grade III disease. When receptor status of
the central portion of each tumour was compared
with histological grading (Table V) receptor status
showed little relationship to Grades I and II but
there was a significant (P<0.05) loss of oestrogen
receptor in the poorly-differentiated tumours,
confirming earlier trends (Pollow et al., 1975; Janne
et al., 1979).
In an attempt to correlate loss of oestrogen
receptor with tumour growth, the oestrogen
receptor status of both central and peripheral
portions of each tumour was re-examined with
respect to menopausal age (Table VI). The tumours
Table IV Classification of tumour incidence relative to
histological grading and menopausal age
Post-menopausal
age
Grade Pre-menopausal _6y >6y Total
I 4 5 8 17
II 0 5 12 17
III 1 4 8 13264 L. CASTAGNETTA et al.
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Figure 1 Distribution of endometrial cancer patients in relation to calendar and menopausal age. Patients
were divided into 3 groups: Group A (pre-menopausal), Group B (. 6 y post-menopausal), and Group C (>6 y
post-menopausal).
Table V Histological grading of the central biopsy of
endometrial cancer in relation to its oestrogen receptor
status
Histological grade
Receptor status I II III Total
Functional
(+/+) 7 8 4 19
Abnormal
(+/0,0/+,0/0) 6 3 9 18
Total 13 11 13 37
showing unusual receptor distribution (+/0) and
(0/+) were combined together as containing non-
functional receptor. The data in Table VI are
consistent with the view that there are 2 types of
endometrial cancer. A similar model incorporating 2
different types of breast cancer has been proposed
(Bross et al., 1968; Baum, 1977). For endometrial
cancer one type, normally associated with the meno-
pause, is initially hormone dependent but rapidly
loses hormone dependence as it ages (less than half-
5/11-of the receptor-positive peripheral sections
have corresponding receptor-positive centres). The
other, occurring several years after menopause is
likely, if receptor-positive, to have functional
Table VI Receptor status of central (c) and peripheral (p)
portions of tumour in relation to post-menopausal age
Receptor status
Positive Abnormal Negative
Menopausal
status c p c p c p
Pre-menopausal
(n=5) 2 3 2 1 1 1
Post-menopausal <6y'
(n= 12) 5 11 3 0 4 1
Post-menopausal>6y
(n=20) 12 15 1 3 7 2
Post-menopausal patients were divided into 2 groups of
greater or less than 6y ofpost-menopausal age. Abnormal
receptor status combines both (+/0) and (0/+) patients.
oestrogen receptor throughout the tumour and so
should reflect a good chance of extended response
to endocrine therapy.
Discussion
The success of oestrogen and progesterone receptor
status as indices of both prognosis and potential
response to endocrine therapy in breast cancer
0
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(Edwards et al., 1979; Hawkins et al., 1980; Leake
et al., 1981a) has led to attempts to use receptor
status in the management of endometrial cancer.
Preliminary results suggest that oestrogen and
progesterone receptor status might well be useful in
predicting response to endocrine therapy (Benraad
et al., 1980) although this view does not yet have
universal support (Hoffman & Siiteri, 1980). The
success of the various treatments of primary
endometrial cancer (Hunter et al., 1980) have
meant that data on the prognostic value of receptor
status are very limited. However, in our study, 5
patients have so far relapsed and each has had a
receptor-negative (0/0) result for the central portion
of tumour although, in two cases, the peripheral
portion was receptor-positive. In Sicily, endometrial
cancer is often more advanced on first examination
than it is in other countries. The tumours are often
very large and more likely to be histologically
classified as Grade III. It has, therefore, been
possible to look at oestrogen receptor distribution
across individual tumours in relation to growth
patterns.
To compare concentration of receptor between
different parts of the same tumour and between
different tumours, it was found more meaningful to
express both ERC and ERn content relative to the
DNA content of the original homogentate.
Comparison of receptor content in the central and
peripheral portions of the same tumour (Table 1)
suggested that the peripheral portion is significantly
more likely to contain functional oestrogen receptor
than the central portion (P<0.02). This is
consistent with the view that most endometrial
cancer is initially hormone dependent but that the
older parts of the tumour eventually lose
dependence (a trend supported by the data on very
large tumours-Table II). Identification of the
central part of the tumour as being the oldest part
is convenient but, perhaps, inaccurate. In an
equivalent study on large breast cancer biopsies
(Silversward et al., 1980), qualitatively similar
conclusions were reported in that receptor
concentration is low at the centre and much higher
at the periphery of the tumour-although this is
not always the case (Tilley et al., 1978). A study of
the receptor status of metastatic disease would be
valuable in indicating which parts of the primary
are most likely to give rise to secondary deposits.
Measurement of concentration of receptor (Table
III) indicates that loss of functional receptor is
perhaps an all-or-none phenomenon rather than a
gradual process, since those tumours which did
contain receptor-positive central portions showed
no trend to lower receptor concentration at the
centre. This suggests that the growth patterns of
breast and endometrial cancer may differ in this
respect since the loss of receptor-containing cells in
breast cancer seems to be more gradual
(Silversward et al., 1980). Abnormal receptor status
was surprisingly common and, in particular, the
occurrence of receptor in the nuclear fraction alone
was much higher than that encountered in breast
cancer (Leake et al., 1981a). This might represent a
stage in the loss of normal receptor function (Geier
et al., 1980) or a related breakdown in the nuclear
processing mechanism (Horwitz & McGuire, 1978).
A study of protease content and distribution might
be of value. The similarity between mean receptor
concentrations in normal and tumour tissue (Table
3) confirms previous observations (Gurpide et al.,
1976; Pollow et al., 1977). However, when patients
in late post-menopause (>6y) are considered
relative to those in early post-menopause then there
was a significant difference (P<0.01) in mean
total receptor concentration (5.11 +3.57
(12)fmol.jug-1 DNA compared with 2.69+0.76 (5))
possibly indicating an increased chance of response
to hormone therapy and perhaps also a better
prognosis for the late menopausal group.
The data comparing receptor status and
histological grading confirmed that of most other
workers (Pollow et al., 1975; Feil et al., 1978;
Janne et al., 1979; Hunter et al., 1980) in showing
that, apart from an increase in receptor-negativity
in Grade III disease, receptor status and
histological grade are unrelated. This study
contained a much larger proportion of tumours of
histological Grade III and so the tendency for them
to be receptor-negative was significant for the first
time.
Since the change from receptor-positive to
receptor-negative status in biopsies from peripheral
and central portions of the same tumour is very
marked in the immediate post-menopausal disease
(0-6y, Table VI), it would be reasonable to suggest
that this might indicate the onset of hormone-
independent disease typical of poorly-differentiated
tissue. In fact, the proportion of patients in the 0-
6y post-menopausal group, who had Grade III
tumours, was not significantly raised relative to the
remainder. Further, since only 5 patients overall
have so far relapsed it is not yet possible to say to
what extent relapse is more rapid in receptor-
negative patients within this group, although
preliminary data clearly suggest that a receptor-
negative central biopsy is an indication of an early
relapse.
In conclusion oestrogen status of large
endometrial cancers, particularly those from women
immediately post-menopausal, can change from
positive at the periphery to negative at the centre.
The disease in women in this early post-menopausal
group is very likely to lose hormonal dependence266 L. CASTAGNETTA et al.
whereas hormone-dependent disease in older
women is much less likely to changes. Where
possible biopsies of both central and peripheral
portions of endometrial cancer are recommended.
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